Abstract. The 1 The following trival names of the steroids have been used: Norethindrone acetate: 17ct-ethynyI-17ß-hydroxy-4-oestren-3-one-17ß-acetate. Northindrone: 17cc-ethynyl -17ß-hydroxy-4-oestren-3-one.
Norethindrone acetate has been widely used as a progestogenic component of oral pills. The suc¬ cessful use of this steroid through the subdermal route was first reported by Laumas and associates (Bhatnagar et al. 1975 ) who suggested the feasibility of the use of a single silastic capsule releasing NETA for contraception in women (Takker et al. 1978) . In a previous communication (Singh et [6,7-3H] progesterone (S.A. 55.7 Ci/mmole -New England Nuclear Corp. Boston); [ 1,2,6,7-3H] Plasma half-lives of NETA The initial a-t'/2 before the insertion of implant (9.0 ± 0.2 min) was similar to the half-life at 1 week (7.0 ± 0.6 min), 1 month (5.5 ± 0.7 min), 2 months (7.0 ± 0 min) and 6 months (9.7 ± 2.1 min) after implant insertion. The ß-tVe was found to be 51.9 ±3.6 h before insertion of implant and Fig. 1 but at 1 month after the insertion of implant. As in Fig. 1 has further been suggested that the suppressive effect on the production of ovarian steroids may be directly related to the effect on gonadotrophin production (Rahman et al. 1977) . It has been demonstrated that administration of small doses of norgestrel reduces the ability of the corpus luteum to synthesize progesterone from pregnenolone in vitro (Mukherjee et al. 1972 These studies thus show that long-term exposure of women to NETA released through subdermal silastic implant may increase its clearance with a rapid metabolism into active metabolite NET which in concert with NETA may contribute to its action.
